Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
170 hedge funds and large institutions have $2.3B invested in Intra-Cellular Therapies Inc. in 2021 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 50 increasing their positions, 66 reducing their positions, and 29 closing their positions.
24% more call options, than puts
Call options by funds: $22.7M | Put options by funds: $18.3M
8% more capital invested
Capital invested by funds: $2.14B → $2.3B (+$169M)
4% less funds holding
Funds holding: 178 → 170 (-8)
21% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 29
24% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 66
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$73.6M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$40.5M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$11.7M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$9.74M |
| 5 |
BlackRock
New York
|
+$9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$27.6M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$15.3M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$13.7M |
| 4 |
SC
Samlyn Capital
New York
|
-$10.1M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$8.54M |
ITCI Hedge Fund Activity: Q1 2021 in Review
170 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2021, worth a combined $2.3B — up 7.9% from $2.14B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ITCI and 23 opened new positions — a net loss of 6 holders — while 66 trimmed existing stakes and 50 added.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $73.6M. The largest seller was Millennium Management, cutting an estimated $27.6M.
- 170 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2021, down from 178 in Q4 2020.
- Funds reported $2.3B of Intra-Cellular Therapies Inc. stock for Q1 2021, up 7.9% quarter-over-quarter.
- 23 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2021 and 29 closed out, a net change of -6 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q1 2021 was Lord, Abbett & Co, an estimated $73.6M added.
- The largest Intra-Cellular Therapies Inc. seller in Q1 2021 was Millennium Management, an estimated $27.6M sold.
Based on aggregated 13F filings for Q1 2021.